CNBC Top NewsCodex · 实盘不做把握 8/10🔁 +1 同一事件
北京时间·🕒 发布 02:24:09时区推断·⟳ 抓取 02:25:20·⚡ 决策 07-30 02:26:43 +1m23s·89.8 天前
Hims & Hers遭FTC及州监管起诉，涉及隐私、计费和订阅取消指控
FTC起诉指控Hims & Hers误导消费者隐私保护、处方收费时点和订阅取消流程，属于公司级新增监管利空。
📄 原文CNBC Top News↗ 原文
Hims and Hers shares fall 10% as FTC sues company over data, billing practices
Shares of telehealth company Hims & Hers Health fell sharply Wednesday after the Federal Trade Commission sued the comp…
不做 Hims & Hers Health（HIMS.US）
近72小时已命中07-29 10:56同一FTC及州监管起诉催化；本条CNBC为重复转述，不重复出卡、不重复开空或延长风险窗口。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 2026-07-29官方确认/否认Hims & Hers IR/公司回应声称一手 · 未核验已处理消息库显示07-29 10:56已有“Hims & Hers遭FTC及州监管起诉，公司回应称将抗辩”的同一催化决策。市场反应:HIMS.US盘中跌至25.675美元，较前收29.32美元下跌12.43%。
- CNBC转述FTC起诉内容、公司否认指控，并称股价周三大幅下跌。市场反应:同一事件已在盘中价格中反映。
关键理由
- FTC起诉指控Hims & Hers误导消费者隐私保护、处方收费时点和订阅取消流程，属于公司级新增监管利空。
- 但近72小时已处理过同一具体催化，当前CNBC稿只是后续媒体转述，不应重复出卡或重复延长风险窗口。
- Hims & Hers盘中已跌约12%，显示市场已对同一监管事件进行即时重定价。
主要风险
- 若后续披露罚金、禁令、和解金额或经营整改约束显著高于此前15百万美元计提，需由新信号重新研判。
反向证据
- 做空前查反向 · 来源 kb_search · 影响 none
内部KB未命中足以改变方向的新反证；但查重库已命中同一具体催化，按去重纪律不再重复交易或输出风险行。
检索:Hims Hers FTC lawsuit privacy billing cancellation July 2026
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 2,223 字
Shares of telehealth company Hims & Hers Health fell sharply Wednesday after the Federal Trade Commission sued the company, alleging it misled consumers about privacy protections, billing practices and subscription cancellations.
The FTC, joined by Los Angeles County and Utah, alleged Hims & Hers shared users' sensitive health information with online advertising platforms including Meta Platforms and Snap Inc. through tracking technologies embedded on its website. The agency said the company's practices were inconsistent with promises it made to protect users' health data.
The FTC also accused Hims & Hers of charging customers for prescriptions before they have spoken with a healthcare provider. The agency alleges many customers are billed after completing an intake form rather than after a consultation with a medical professional.
The regulator further alleges the company made it difficult for users to cancel subscriptions.
Hims & Hers denied the allegation in a post on X, saying the lawsuit "disregards substantial evidence" provided during the FTC's nearly three-year investigation into the company and "contorts the law to try to manufacture claims."
The company said it is confident in its position and will "vigorously defend" itself.
The lawsuit comes as Hims & Hers has emerged as one of the largest telehealth providers in the fast-growing market for weight loss medications. The company offers virtual appointments and prescriptions for treatments including weight loss drugs, erectile dysfunction, hair loss and mental health medications, which are shipped directly to consumers.
The investigation by the FTC dates back to October 2023. CNBC has reported on several probes into Hims & Hers' business practices, including its Super Bowl ad and compounded weight loss drugs.
In April, the FTC formally communicated the findings of its probe started in 2023 to the company and settlement discussions began. In May, Hims & Hers disclosed a $15 million probable-loss accrual related to the matter, warning the final cost could be materially higher. The company said it made a settlement offer without admitting wrongdoing.
Wednesday's lawsuit escalates that dispute, with regulators pushing new claims.
The FTC, joined by Los Angeles County and Utah, alleged Hims & Hers shared users' sensitive health information with online advertising platforms including Meta Platforms and Snap Inc. through tracking technologies embedded on its website. The agency said the company's practices were inconsistent with promises it made to protect users' health data.
The FTC also accused Hims & Hers of charging customers for prescriptions before they have spoken with a healthcare provider. The agency alleges many customers are billed after completing an intake form rather than after a consultation with a medical professional.
The regulator further alleges the company made it difficult for users to cancel subscriptions.
Hims & Hers denied the allegation in a post on X, saying the lawsuit "disregards substantial evidence" provided during the FTC's nearly three-year investigation into the company and "contorts the law to try to manufacture claims."
The company said it is confident in its position and will "vigorously defend" itself.
The lawsuit comes as Hims & Hers has emerged as one of the largest telehealth providers in the fast-growing market for weight loss medications. The company offers virtual appointments and prescriptions for treatments including weight loss drugs, erectile dysfunction, hair loss and mental health medications, which are shipped directly to consumers.
The investigation by the FTC dates back to October 2023. CNBC has reported on several probes into Hims & Hers' business practices, including its Super Bowl ad and compounded weight loss drugs.
In April, the FTC formally communicated the findings of its probe started in 2023 to the company and settlement discussions began. In May, Hims & Hers disclosed a $15 million probable-loss accrual related to the matter, warning the final cost could be materially higher. The company said it made a settlement offer without admitting wrongdoing.
Wednesday's lawsuit escalates that dispute, with regulators pushing new claims.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。